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Edited by Gianni CesareniAbstract Even if template sequence of hTR played an essential
role in telomere binding, a 326 nucleotide fragment of hTR con-
taining template, pseudoknot, and CR4–5 domains is critical for
both binding with telomeric DNA and reconstitution of telome-
rase activity. A functional study with antisense oligonucleotides
suggested that targeted disruption of the template region eﬃ-
ciently abrogated both telomeric DNA binding and telomerase
activity, whereas disruption of the CR4–5 region induced only
loss of telomerase activity. hTR interacts with telomeric DNA
via structural region composed of the template, pseudoknot,
and CR4–5 domains, however, each structural domain plays a
distinct role in telomere binding and telomerase activity
reconstitution.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Telomerase1. Introduction
The synthesis of telomeric DNA requires at least two telo-
merase components: the protein catalytic subunit (hTERT)
and the RNA subunit (hTR). A secondary structure of hTR
based on phylogenetic comparative analysis shows that hTR
contains several structural domains, which are conserved in
all vertebrates [1]. The conserved secondary structure is com-
posed of several distinct domains, which include the template,
pseudoknot, CR4–5, Box H/ACA, and the CR7 domains.
Human telomerase activity can be reconstituted in three dif-
ferent in vitro systems, such as addition of in vitro transcribed
hTR to rabbit reticulocyte lysates (RRLs) expressing hTERT
[2], micrococcal nuclease (MNase, Pharmacia) treated cancer
cell lysate [3], or recombinant hTERT puriﬁed from baculovi-
rus-infected insect cells [4]. In vitro assembly reactions using
deleted or site-directed hTR mutants suggest that the struc-
tural domains of hTR play critical roles in telomerase activa-
tion. Wright and co-workers [5] reported that a region
between nucleotides +33 and +325 is required for telomerase
enzymatic activity. It was also suggested that a 159 nucleotide
fragment of hTR is suﬃcient for a stable interaction between
hTR and hTERT [6]. The CR4–5 and pseudoknot domains*Corresponding author. Fax: +822 361 7623.
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doi:10.1016/j.febslet.2004.11.058have also been suggested as critical domains for the activation
of this enzyme [7,8]. However, the signiﬁcance of the structural
domains of hTR in the binding with telomeric DNA and the
eﬀects that this binding has on enzymatic activity have not
been elucidated.2. Materials and methods
2.1. Preparation of hTR
We generated truncated hTR mutants based on the secondary struc-
ture of hTR [2]. Full length or truncated mutants were obtained by
PCR ampliﬁcation of HT1080 genomic DNA with oligonucleotide
primers encoding the appropriate hTR sequences: D1 (+1 and +183),
D2 (+1 and +212), D3 (+1 and +326), D4 (+1 and +363), D5 (+1
and +407), D6 (+1 and +451), and D7 (+64 and +451). The PCR prod-
ucts were cloned into pGEM-T vector (Promega) containing the T7
RNA polymerase promoter sequence at the 5 0 end of the multiple clon-
ing region. Full length or truncated mutants of hTR were transcribed
in vitro using the RiboProbe transcription system (Promega).
2.2. Preparation of hTERT
Insert DNA containing the entire hTERT coding sequences fused
with HA-epitope tag at C-terminal was subcloned into pCI neo vector
at EcoRI–SalI sites. hTERT-HA protein was synthesized by using a
RRL transcription/translation system (TNTR System; Promega).
hTERT-HA cDNA was added to RRL at a concentration of 0.04
lg/lL and incubated at 30 C for 90 min. The translation product
was used for in vitro telomerase reconstitution.
2.3. In vitro telomerase reconstitution and TRAP assay
Human telomerase was reconstituted in a 5 lL reaction mixture con-
taining 150 ng of in vitro transcribed hTR, 2 lL of in vitro synthesized
hTERT in RRL, and 2 lL of fresh RRL. The mixture was then incu-
bated at 30 C for 90 min and diluted 10-fold in Chaps lysis buﬀer (10
mM Tris–Cl, pH 7.5, 1 mM MgCl2, 1 mM EGTA, 0.1 mM PMSF,
0.5% Chaps, and 10% glycerol). Telomerase activity was determined
by using the TRAP assay as described by Kim and Wu [9]. The relative
activity of the telomerase was determined using the following formula:
TPG ð%Þ ¼ Sample½ðT  BÞ=CT 
wild-type½ðT  BÞ=CT   100
where TPG is the telomerase activity, T the total intensity of telome-
rase mediated bands, B the intensity of the negative control, and CT
the intensity of the internal control.
To determine the eﬀect of antisense oligonucleotide on the assembly
of active telomerase, 50 pmol of oligonucleotide was incubated with
hTR at 30 C for 15 min prior to the addition of in vitro synthesized
hTERT.
2.4. Electrophoretic mobility shift assay (EMSA)
EMSA was used to identify the telomere binding ability of the hTR
mutants by using a 32P-labeled telomeric sequence (TTAGGG)n. In
standard binding reactions, 150 lg of a hTR mutant was incubatedblished by Elsevier B.V. All rights reserved.
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Tris–Cl, pH 7.5, 5 mM MgCl2, 1 mM EDTA, 50 mM NaCl, 1 mM
DTT, 5% glycerol, and 66 ng/lL poly[dI ÆdC]) at 37 C for 30 min.
The binding complex was then irradiated with 15 mJ in XL-1500
UV crosslinker (Spectronic Corporation, NY, USA) for 5 min. Two
microliters of 80% glycerol was added to 8 lL of the reaction mixture
and electrophoresed in 1.5 % agarose gel or 6% polyacrylamide gel in
0.5· TBE buﬀer (89 mM Tris–borate and 2 mM EDTA) at 4 C, 80 V
for 4–5 h.
To determine the eﬀect of antisense oligonucleotide on complex for-
mation, a 100-fold molar excess of the appropriate unlabeled oligonu-
cleotide was added to the reaction mixture, prior to adding labeled
probe and then incubated at 37 C for 15 min. The primer sequences
used for antisense analysis were as follows: 5 0-tcagttagggttagac-30 for
the template domain, 5 0-gtttgctctagaat-3 0 for the pseudoknot domain,
and 5 0-gctgacagagcccaact-3 0 for the CR4–5 domain. Antisense oligo-
nucleotide was designed to target the unpaired region in the functional
domain of hTR based on its proposed secondary structure by Chen
et al. [1] (Fig. 1).
2.5. Immunoprecipitation
Fifty microliters of assemble reaction mixtures was precipitated by
adding anti-HA mouse monoclonal antibody (Santa Cruz Biotechnol-
ogy, Inc) and 70 ll of protein G agarose (Santa Cruz Biotechnology,
Inc.) in IP buﬀer (50 mM HEPES, pH 7.6, 100 mM NaCl, 0.1% NP-
40, 0.2 mM EGTA, 1 mMMgCl2, and 10% glycerol). The agarose pel-
let obtained was washed in 20 mM HEPES, pH 7.6, 20% glycerol, 10Fig. 1. Secondary structure of hTR and schematic representation of hTR m
sequence and several conserved domains including pseudoknot, CR4–5, Bo
location of antisense oligonucleotide against template, pseudoknot, and CR
with the conserved structural domains. (C) hTR mutants were in vitro tran
amount.mMNaCl, 0.2 mM EGTA, 1 mMMgCl2, 0.1% NP-40, and 0.1% BSA.
2, 10, and 30 ll of beads were analyzed by TRAP, and by Western blot
and Northern blot analyses, respectively.3. Results
3.1. Minimally required hTR for telomeric DNA binding
We generated seven diﬀerent hTR truncation constructs
based on the secondary structure (Fig. 1A). These truncations
were designed to delete the structural domains step-wise from
the 3 0 or 5 0 end of hTR (Fig. 1B). The size and integrity of in
vitro transcribed hTR were conﬁrmed by agarose electropho-
resis using a size marker (Fig. 1C).
To identify the telomere binding region of hTR, EMSA was
performed using in vitro transcribed hTR and the single strand
telomeric repeat sequence (TTAGGG)n. At ﬁrst, various
lengths of (TTAGGG)n were added to the reaction to deﬁne
the eﬀective telomeric length on hTR–telomeric DNA complex
formation (Fig. 2A). A strong complex was observed only with
18mer (TTAGGG)3 (lane 2). Shorter (lane1) or longer (lanes
3–5) telomeric sequences than 18mer did not form any detect-
able complexes. This result suggests that the length of the telo-utants. (A) The secondary structure of hTR is composed of a template
x H/ACA, and the CR7 domains (in box). Red regions showed the
4–5 domains, respectively. (B) hTR mutant constructs are represented
scribed and electrophoresed to verify the accurate molecular size and
Fig. 2. Complex formation between in vitro transcribed hTR and
telomeric DNA. (A) The eﬀect of telomeric DNA length on DNA–
RNA complex formation was evaluated by diﬀerent lengths of 32P-
labeled (TTAGGG)n (n = 2, lane 1; n = 3, lane 2; n = 4, lane 3; n = 5,
lane 4; n = 6, lane 5). (B) EMSA was carried out using 32P-labeled
telomeric DNA, (TTAGGG)3 and various truncated hTR mutants
transcribed in vitro. One picomole of 32P-labeled probe was incubated
without (lane 1) or with (lanes 2–8) the truncated hTR mutants.
Reactions were visualized by autoradiography (top). Isolated hTR
mutants were hybridized with 32P-labeled oligonucleotides comple-
mentary to hTR nt+164 to nt+183 (bottom).
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meric DNA.
We then identiﬁed the minimally required structural do-
mains of hTR for telomere binding using hTR mutants (Fig.
2B, top). A weak binding complex was observed with D1 (1–Fig. 3. In vitro reconstitution of telomerase activity. (A) The in vitro recon
hTERT, and fresh RRL. Lanes 1–5: 0, 10, 50, 150, 300 ng of hTR; lanes 6–9:
fresh RRL. (B) Diﬀerent mutants were reconstituted with hTERT containi
telomerase activity of the immunoprecipitate was determined by TRAP assay
analysis was performed with anti-HA monoclonal antibody. (D) Before (top)
Northern blot hybridization analysis with an hTR-speciﬁc probe.183) and D2 (1–212) mutants. The RNA–DNA complex for-
mation increased gradually from D3 (1–326) to D6 (1–451).
Mutants D3 (1–326), D4 (1–363) and D5 (1–407) showed
13.2%, 27.4% and 14.6% of the telomeric DNA binding activ-
ity of the wild-type D6, respectively. In contrast, D7 (64–451)
did not form a complex with telomeric DNA. These EMSA re-
sults suggest that the template sequences of hTR play an essen-
tial role in binding with telomeric DNA and that the minimally
required hTR for this binding is a 326 nt fragment containing
the template, pseudoknot, and CR4–5 domains. To monitor
the amount and integrity of the input hTR mutants in the
binding assay, we isolated RNA from mixtures after the bind-
ing reaction and performed Northern blot hybridization with a
hTR-speciﬁc probe (Fig. 2B, bottom). The levels and integri-
ties of hTR mutants in the binding assay were not diﬀerent
from each other.3.2. Minimally required hTR for telomerase reconstitution
To analyze the ability of hTR mutants in reconstituting ac-
tive telomerase, we performed in vitro reconstitution assay
with RRL system expressing hTERT. Telomerase activity in-
creased gradually on adding two essential components of telo-
merase, hTR and hTERT, in a dose-dependent manner (Fig.
3A). We optimized in vitro telomerase reconstitution by add-
ing 150 ng of each hTR transcript, 2 lL of RRL expressing
hTERT, and 2 lL of fresh RRL. D1, D2 and D7 showed no
telomerase activity, whereas D3, D4 and D5 showed 46%,
58.0%, and 32.0% of the telomerase activity of the wild-type
D6, respectively (Fig. 3B). The results showed that 326 nt ofstitution of telomerase was evaluated with various amounts of hTR,
0, 0.5, 1, 2 lL of hTERT synthesized in vitro; lanes 10–12: 0, 1, 2 lL of
ng HA tag and were subjected to anti-HA immunoprecipitation. The
. (C) Before (top) or after (bottom) immunoprecipitation, Western blot
or after (bottom) immunoprecipitation, isolated RNA was subjected to
Fig. 4. Eﬀect of antisense oligonucleotides on the formation of the
RNA–DNA complex and telomerase activity. (A) EMSA was
performed in the absence (lane 1) or in the presence (lanes 2–7) of
competitive primers or antisense oligonucleotides. hTR was incubated
with a non-labeled homologous competitor (lane 2), non-speciﬁc
primer [(TGTGAG)3, lane 3; (TTGGAG)3, lane 4], anti-template
oligonucleotides (lane 5), anti-pseudoknot oligonucleotides (lane 6), or
anti-CR4–5 oligonucleotides (lane 7) prior to adding the 32P-labeled
probe. (B) After incubating hTR with antisense oligonucleotides,
hTERT was added to the reaction and a TRAP assay was performed.
(C) Relative quantitation of the degree of inhibition by antisense
oligonucleotides.
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stitution system. This minimal region for telomerase activity
was concordant with minimal region required for telomere
binding.
3.3. Minimally required hTR for hTERT binding
To evaluate the ability of hTR mutants to associate with
hTERT, each assemble reaction mixture was immunoprecipi-
tated with HA-antibody to HA tag located at the carboxy ter-
minus of hTERT. And the immunoprecipitate was subjected to
Western blot (Fig. 3C) and Northern blot analyses (Fig. 3D).
The amounts of total and precipitated hTERT were similar
for all fractions (Fig. 3C). Despite the same amount of input
hTR mutants in all assemble reaction fractions, mutant D7
spanning nucleotides 64–451 did not co-immunoprecipitate
with hTERT. These results suggest that 1–64 nt structural re-
gion of hTR plays a critical role in the binding with the cata-
lytic subunit of telomerase. Therefore, the mutant D1 spanning
1–183 was suﬃcient for the interaction with hTERT. The rel-
ative ratios of the enzymatic activities, telomeric DNA and
hTERT binding capacities of each hTR mutant are summa-
rized in Table 1. These results show that diﬀerent structural re-
gions of hTR are required for DNA (telomere) binding and for
protein (hTERT) binding.
3.4. Comparison of structural domains of hTR for telomere
binding and telomerase activity by antisense oligonucleotide
As shown in Figs. 2 and 3, minimal sequence of hTR re-
quired for telomere binding and telomerase activity contains
three functional domains, i.e., the template, pseudoknot, and
CR4–5 domains. To evaluate the role of each domain, anti-
sense oligonucleotides were designed to target the unpaired re-
gion of the template, pseudoknot, or CR4–5 domains. Fig. 4A
shows that wild-type hTR forms a strong complex with the
32P-labeled telomeric sequences of (TTAGGG)3 (lane 1). This
RNA–DNA complex formation was competed by adding a
non-labeled homologous competitor (lane 2), but was not
inhibited by any of the non-speciﬁc primers of equal molecular
weight [(TGTGAG)3, lane 3 and (TTGGAG)3, lane 4]. These
ﬁndings suggest that the formation of the hTR–telomere com-
plex is mediated by sequence-speciﬁc recognition. Anti-tem-
plate oligonucleotides completely abolished the RNA–DNA
binding (lane 5), whereas anti-CR4–5 oligonucleotides reduced
RNA–DNA binding by only 4% (lane 7). On the other hand,Table 1
Summary of hTERT biding activity, telomeric DNA binding ability, and te
Telomerase RNA Characterization of structure
hTR D1 (1–183) Truncated 3 0 terminal 268 nt; partly disrupted P1 heli
domain, BoxH/ACA and CR7 domain
hTR D2 (1–212) Truncated 3 0 terminal 239 nt; deleted BoxH/ACA and
hTR D3 (1–326) Truncated 3 0 terminal 125 nt; partly disrupted hypervar
BoxH/ACA and CR7 domain
hTR D4 (l–363) Truncated 3 0 terminal 88 nt; deleted BoxH/ACA and
hTR D5 (1–407) Truncated 3 0 terminal 44 nt; partial disrupted BoxH/A
domain
hTR D6 (1–451) Full length, wild type
hTR D7 (64–451) Truncated 5 0 terminal 64 nt; deleted template region
Relative activity of each mutant was determined by deﬁning the relative lev
mutants is represented symbolically as a relative range: +++++, greater than
between 40+% and 21%; +, between 20% and 1%; , less than 1%.anti-pseudoknot oligonucleotide enhanced the complex forma-
tion (lane 6). We also analyzed the antisense oligonucleotides
eﬀect on telomerase activity (Fig. 4B). Anti-CR4–5 and anti-







x, deleted CR4–5 +++++  
CR7domain +++++  
iable region, deleted ++++ + +++
CR7domain +++++ ++ +++
CA, deleted CR7 ++++ + ++
+++++ +++++ +++++
  
el of activity against wild-type hTR taken as 100%. The activity of all
80%; ++++, between 80% and 61%; +++, between 60% and 41%; ++,
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oligonucleotide also reduced telomerase activity by 25.9%.4. Discussion
The length of the telomeric sequences was found to be crit-
ical for in vitro binding between hTR and telomeric DNA.
Only (TTAGGG)3, 18mer formed a stable complex with
hTR. Telomeric DNA shorter or longer than 18mer did not
form a strong complex, which suggests that telomeric se-
quences shorter than 18mer are too short to form a stable base
pair with hTR. In contrast, longer sequences than 18mer had
been suggested to form secondary structures by themselves,
e.g., the G-quartet [10,11].
It was suggested that nucleotides +33 and +325 of hTR con-
taining the template, pseudoknot, and CR4–5 domains repre-
sent the minimal requirement for telomerase activity in RRL
system. In particular, the integrities of CR4–5 and of the
pseudoknot structure were found to be critical for the reconsti-
tution of telomerase activity in studies using truncated or se-
quence-substituted hTR mutants [3,4]. Direct interaction of
hTR–hTERT was also investigated by using an in vitro telo-
merase reconstitution assay. Autexier et al. [3] reported that
159 nt of hTR is suﬃcient for a stable interaction with hTERT
and found that two distinct hTERT-binding sites existed at
nucleotides +33 and +147 and +164 and +325. However, no
investigation has been conducted on the role of the hTR struc-
tural domains in terms of its binding with telomeric DNA. Our
results showed that the minimal region of hTR required for
telomere binding is a 326 nt fragment of hTR, which contains
the template, pseudoknot and CR4–5 domains. We also con-
ﬁrmed that this 326 nt fragment of hTR is critical for the
expression of telomerase activity. On the contrary, a small
fragment (183 nt) of hTR was suﬃcient for the interaction with
hTERT. Hence, hTR–DNA (telomere) binding needs more
stable structure of hTR than hTR–protein (hTERT) binding
in terms of telomerase activity.
Template domain has known to fold into a long hairpin
structure, in which the template sequence occupies a readily
accessible position [10,12]. Neither in vivo nor in vitro hTR
mapping has conﬁrmed formation of a stable psuedoknot he-
lix. Rather, it has suggested that the pseudoknot domain ex-
ists in two alternative states of nearly equal stability in
solution. One is the previously proposed pseudoknot formed
by pairing with P3 with template region and the other is a
structural P2b loop alone [13]. Disruption of the pseudoknot
domain by antisense oligonucleotide reduced telomerase
activity, but enhanced telomere binding in our study. This
ﬁnding can be partly explained by equilibrium shift phenom-
enon. Theimer et al. [14] showed that mutation in the
pseudoknot domain results in a shift in the equilibrium to-
ward the hairpin form, primarily due to stabilization of the
pseudoknot. With this hairpin form excessiveness, the bind-
ing capacity with telomere may increase even with loss of tel-
omerase activity. In contrast to pseudoknot domain,
disruption of template region by antisense oligoneucleotide
completely blocked telomere binding and thus inhibited telo-
merase activity reconstruction as we assumed based on pre-
vious data.
The role of the CR4–5 domain has not been elucidated, but a
truncated mutant without the CR4–5 domain did not have tel-omerase activity [3]. Stable base pairing of the P6.1 stem was
required for the RNA–protein interaction between the CR4–
5 domain and hTERT [15]. Moreover, mutation of unpaired
nucleotides stem–loop of activation domain abolished enzy-
matic activity [16]. We found that antisense oligonucleotide
targeting the CR4–5 domain only partially inhibited telomeric
DNA–hTR binding, but completely inhibited its enzymatic
activity, suggesting that a minor structural change of its region
can be a good strategy for telomerase inhibition. In previous
study, two hTR mutations were found which allowed RNA–
protein binding but signiﬁcantly impaired telomerase activity
[15]. Similar to this, our results showed that antisense oligonu-
cleotide targeting the pseudoknot and the CR4–5 domain com-
pletely inhibited telomerase activity, but did not inhibit
telomere binding. This ﬁnding suggests that the three struc-
tural domains (template, pseudoknot, and CR4–5 domains)
play distinct functional roles in terms of the activation of telo-
merase and telomere binding. We found that hammerhead
ribozyme targeting the template region of hTR eﬃciently
cleaved hTR in vitro, and stable transfectants of this ribozyme
induced the degradation of target hTR RNA and attenuated
telomerase activity in MCF-7 cells. Moreover, the ribozyme
R1 transfectant displayed a signiﬁcant telomere shortening
and a lower proliferation rate than parental cells. Clones with
reduced proliferation capacity showed enlarged senescence-like
shapes or highly diﬀerentiated dendritic morphologies of apop-
tosis. Ribozyme targeting CR4–5 domain showed weak cleav-
age activity of the target site [17].
It is suggested that each functional domain of hTR may per-
form a diﬀerent regulatory function in terms of telomere bind-
ing and telomerase activity.Acknowledgments: This work was supported by the Korea Sciences
and Engineering Fund through the Cancer Metastasis Research Center
at Yonsei University. We thank S.C. Kim for the gift of hTERT cDNA
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